ADVANCES IN ANTI-TUBERCULOSIS DRUGS
Abstract
Despite the introduction 40 years ago of the inexpensive and effective four-drug (isoniazid, rifampicin, pyrazinamide and ethambutol) treatment regimen, tuberculosis (TB) continues to cause considerable morbidity and mortality worldwide. For the first time since the 1960s, new and novel drugs and regimens for all forms of TB are emerging. Such regimens are likely to utilize both repurposed drugs and new chemical entities, and several of these regimens are now progressing through clinical trials. This article covers current concepts and recent advances in TB drug discovery and development.
Key Words: MDR-TB, XDR-TB, TDR-TB, Bedaquiline, Delamanid
Â
Downloads
Download data is not yet available.
Statistics
137 Views | 161 Downloads
How to Cite
1.
Pradhan S, Mathur A, Patil A. ADVANCES IN ANTI-TUBERCULOSIS DRUGS. JDDT [Internet]. 14Sep.2014 [cited 24Jan.2021];4(5):69-3. Available from: http://jddtonline.info/index.php/jddt/article/view/965
Section
Review
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).